Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium GlobeNewswire - Tue Apr 14, 7:30AM CDT

DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics Announces CFO Transition GlobeNewswire - Fri Apr 10, 4:00PM CDT

DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain GlobeNewswire - Tue Mar 31, 7:30AM CDT

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Thu Mar 19, 5:30AM CDT

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics to Present at 38th Annual ROTH Conference GlobeNewswire - Thu Mar 12, 7:30AM CDT

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 GlobeNewswire - Mon Mar 9, 7:30AM CDT

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Mon Feb 23, 7:00AM CST

DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics Business Wire - Thu Jan 15, 3:10PM CST

Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos...

PTHS : 23.02 (+0.07%)
HRZN : 4.38 (-1.13%)
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance GlobeNewswire - Tue Jan 13, 7:30AM CST

DURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
HRZN : 4.38 (-1.13%)
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice GlobeNewswire - Mon Jan 5, 6:30AM CST

Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients...

PTHS : 23.02 (+0.07%)

Barchart Exclusives

Applebee’s and IHOP Owner Dine Brands Looks Ripe For A Buyout Barchart - Sun Apr 19, 2:18PM CDT
Dine Brands has already rallied on activist pressure, but with Applebee’s and IHOP still trading below their strategic value, private equity could be the next catalyst. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.